HTG Molecular Diagnostics, Inc., commonly referred to as HTG, is a pioneering company headquartered in the United States, specialising in molecular diagnostics. Founded in 2006, HTG has established itself as a leader in the development of innovative technologies for gene expression profiling and biomarker discovery, primarily serving the oncology and research sectors. The company’s flagship products, including the HTG EdgeSeq platform, offer unique solutions for high-throughput gene expression analysis, enabling precise and efficient data generation. HTG's commitment to advancing personalised medicine has positioned it favourably within the competitive landscape of molecular diagnostics, with notable achievements in enhancing patient outcomes through targeted therapies. With a strong operational presence across key regions in the US, HTG continues to drive advancements in molecular diagnostics, solidifying its reputation as a trusted partner in the healthcare industry.
How does HTG Molecular Diagnostics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
HTG Molecular Diagnostics, Inc.'s score of 18 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
HTG Molecular Diagnostics, Inc., headquartered in the US, currently does not have available data on carbon emissions, as no specific emissions figures have been provided. Consequently, there are no reported Scope 1, 2, or 3 emissions figures to analyse. In the absence of concrete emissions data, it is important to note that the company has not outlined any specific reduction targets or climate commitments. This lack of publicly available information may suggest that HTG Molecular Diagnostics is still in the early stages of developing a comprehensive climate strategy or reporting framework. As the industry increasingly prioritises sustainability and carbon footprint reduction, HTG Molecular Diagnostics may benefit from establishing clear climate commitments and reduction initiatives to align with global standards and expectations.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
HTG Molecular Diagnostics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.